Results 81 to 90 of about 495,708 (385)

Lessons Learned From a Delayed‐Start Trial of Modafinil for Freezing of Gait in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Freezing of gait (FOG) in people with Parkinson's disease (PwPD) is debilitating and has limited treatments. Modafinil modulates beta/gamma band activity in the pedunculopontine nucleus (PPN), like PPN deep brain stimulation. We therefore tested the hypothesis that Modafinil would improve FOG in PwPD.
Tuhin Virmani, Lakshmi Pillai, Reid D. Landes, Aliyah Glover, Shannon Doerhoff, Jennifer Kleiner, Mitesh Lotia, Rohit Dhall, Edgar Garcia‐Rill   +8 more
wiley   +1 more source

Placebos in 19th Century Medicine: A Quantitative Analysis of the BMJ [PDF]

, 2012
Objective: To provide the first quantitative data on the use of the term “placebo” in the 19th century. Design: Computer search of BMJ’s archival database from January 1840 (the first issue) through December 1899 for uses of the words “placebo(s ...
Kaptchuk, Ted Jack, Raicek, Jacqueline E, Stone, Bradley H   +2 more
core   +1 more source

Applying an Ethical Lens to the Treatment of People With Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The practice of neurology requires an understanding of clinical ethics for decision‐making. In multiple sclerosis (MS) care, there are a wide range of ethical considerations that may arise. These involve shared decision‐making around selection of a disease‐modifying therapy (DMT), risks and benefits of well‐studied medications in comparison to
Methma Udawatta, Farrah J. Mateen
wiley   +1 more source

From substance to process: A meta-ethnographic review of how healthcare professionals and patients understand placebos and their effects in primary care

Health, 2018
Research suggests that a ‘placebo’ can improve conditions common in primary care including pain, depression and irritable bowel syndrome. However, disagreement persists over the definition and clinical relevance of placebo treatments. We conducted a meta-
Doug I Hardman, A. Geraghty, G. Lewith, M. Lown, Clelia Viecelli, F. Bishop   +5 more
semanticscholar   +1 more source

Clinically Relevant Outcome Measures in Women With Adrenoleukodystrophy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Adrenoleukodystrophy is a rare inherited peroxisomal disease caused by pathogenic variants in the ABCD1 gene located on the X chromosome. Although the most severe central nervous system and adrenal complications typically affect only men with adrenoleukodystrophy, the majority of women develop myeloneuropathy symptoms in adulthood.
Chenwei Yan, Elizabeth I. Pierpont, Amena S. Fine, Reena V. Kartha   +3 more
wiley   +1 more source

‘Placebos’ and the logic of placebo comparison [PDF]

, 2012
Robin Nunn has argued that we should stop using the terms ‘placebo’ and ‘placebo effect’. I argue in support of Nunn’s position by considering the logic of why we perform placebo comparisons.
Turner, Andrew
core   +2 more sources

Impact of Asymptomatic Intracranial Hemorrhage on Outcome After Endovascular Stroke Treatment

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Endovascular treatment (EVT) achieves high rates of recanalization in acute large‐vessel occlusion (LVO) stroke, but functional recovery remains heterogeneous. While symptomatic intracranial hemorrhage (sICH) has been well studied, the prognostic impact of asymptomatic intracranial hemorrhage (aICH) after EVT is less certain ...
Shihai Yang, Chengsong Yue, Zhuang Li, Xiaolei Shi, Haoxuan Zhu, Jie Yang, Linyu Li, Jiaxing Song, Shitao Fan, Gaoming Li, Wenzhe Sun, Zhixian Ye, Jiacheng Huang, Dahong Yang, Jinfu Ma, Xu Xu, Zhixi Wang, Lilan Wang, Guojian Liu, Fengli Li, Changwei Guo, Li Qi, Wenjie Zi   +22 more
wiley   +1 more source

Great Expectations: The Evolutionary Psychology of Faith-Healing and the Placebo Effect [PDF]

, 2002
non
Humphrey, Nicholas
core  

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. [PDF]

, 2004
BACKGROUND: An open-label study indicated that selective depletion of B cells with the use of rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To confirm these observations, we conducted a randomized, double-blind,
Close, DR, Edwards, JCW, Emery, P, Filipowicz-Sosnowska, A, Shaw, T, Stevens, RM, Szczepanski, L, Szechinski, J   +7 more
core   +1 more source

Improvements in Health‐Related Quality of Life With Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial

Arthritis Care &Research, EarlyView.
Objective Although treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL ...
Austin Barry, Bryant R. England, Harlan Sayles, Lindsay N. Helget, Maria Androsenko, Hongsheng Wu, Kaleb Michaud, Bridget Kramer, Jeff A. Newcomb, Mary T. Brophy, Anne Davis‐Karim, Ryan Ferguson, Michael H. Pillinger, Tuhina Neogi, Paul M. Palevsky, James R. O'Dell, Ted R. Mikuls   +16 more
wiley   +1 more source